Clinical trials: AdV Reactivation
ADV Infection Post Allo-HSCT
Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT
Human Adenovirus-specific T-cells can persist and augment impaired adenovirus immune response post allogeneic haematopoietic stem cell transplant, and reduce the requirement for antiviral therapy without toxicity or increasing…
- Trial name
- ASPIRE (NCT01822093)
- Testing
- Cytovir-ADV
- Where
- 3 sites in United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cell Medica Ltd
Infectious Complications Following HSCT
Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT
DESIGN: Disease registry - non-interventional. INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.
- Trial name
- EPROS (NCT02873325)
- Testing
- antiviral therapies for CMV and/or ADV
- Where
- 2 sites in United Kingdom
- Volunteers
- 1 people
- Sponsor
- Cell Medica Ltd